Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Black Diamond Therapeutics (NASDAQ: BDTX ) is gearing up to report initial results from its phase 2 study using BDTX-1535 targeting 1st-line EGFR mutant non-small cell lung cancer [NSCLC] patients in Q1 of 2025. There might also be an additional update of data He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news re ...